OncoMatch

OncoMatch/Clinical Trials/NCT07689019

Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment

Is NCT07689019 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies multiple treatments including Transcutaneous Electrical Nerve Stimulation and Far-Infrared Therapy for head and neck cancer (h&n).

NARecruitingBuddhist Tzu Chi General HospitalNCT07689019Data as of Jul 2026Location: Taiwan

Treatment: Transcutaneous Electrical Nerve Stimulation · Far-Infrared TherapyThis clinical trial aims to evaluate whether far infrared radiation therapy and transcutaneous electrical nerve stimulation can reduce treatment-related side effects in patients with head and neck cancer undergoing concurrent chemoradiotherapy. The primary objectives of this study are to determine whether far infrared radiation therapy and transcutaneous electrical nerve stimulation can improve shoulder pain and disability, cervical range of motion, maximum interincisal distance, oral mucositis, systemic inflammation, and chemotherapy-induced nausea and vomiting. Participants will be randomly assigned to one of three groups: Group A will receive standard care (control group); Group B will receive standard care plus transcutaneous electrical nerve stimulation; and Group C will receive standard care plus far infrared radiation therapy combined with transcutaneous electrical nerve stimulation. The intervention will be administered over two cycles of concurrent chemoradiotherapy, for a total of 10 intervention days. During each treatment cycle, participants in the intervention groups will receive the assigned treatment once every morning and once every evening for five consecutive days. Outcome assessments will be performed at three time points during each treatment cycle: before the intervention on Day 1 (baseline), after the intervention on Day 3, and after the intervention on Day 5.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Transcutaneous Electrical Nerve StimulationFar-Infrared Therapy

Cancer type

Head and Neck Squamous Cell Carcinoma

Demographics

Ages 30–85

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07689019 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 85 years or younger and at least 30 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify